Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients

September 8, 2010 By Bio-Medicine.Org

ST. LOUIS, Sept. 8 /PRNewswire-FirstCall/ — Stereotaxis, Inc.
(Nasdaq:
STXS
) highlighted significant new additions to the body of
evidence demonstrating exceptional clinical outcomes achieved with
its Niobe® Magnetic Navigation System in ventricular
tachycardia (VT) ablation.

At the European Cardiology Society Annual Congress in Stockholm
last week, the research team led by Dr. Tamas Szili-Torok from the
Erasmus Medical Center in Rotterdam presented the first comparative
trial in a prospective study of 64 consecutive VT patients,
comparing Stereotaxis VT ablation to conventional, non-magnetic
ablation.  Acute success was achieved in 97% of the
Stereotaxis VT ablation group versus 81% of the manual ablation
group.  Patients in the Stereotaxis VT group averaged 50% less
x-ray exposure, and after a year, only 14% VT recurrence, versus a
50% recurrence rate among manual ablation patients.  A
remarkable 25% reduction in total procedure time was achieved in
the Stereotaxis VT group compared to the manual group.

There were no major complications in the Stereotaxis VT group
compared to one death in the non-Stereotaxis group, representing a
4% major complication rate.

“The use of Stereotaxis offers major advantages for the ablation
of VT,” said Dr. Szili-Torok. “We have adopted a 100% utilization
rule for our Stereotaxis lab for cardiac arrhythmias due to the
significant benefits for our patients as well as for us as
operators.”

Further, Dr. Arash Arya and colleagues from the University of
Leipzig Heart Center in Leipzig, Germany published data from a
series of 30 consecutive patients who were suffering from “VT
storm,” which is three or more VT episodes in a 24 hour period that
trigger a shock treatment from an implanted defibrillator device.
 While treating VT Storm is extremely challenging, Dr. Arya
reported that 70% of the patients

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech